Global and China Monoclonal antibodies (mAbs) Biosimilars Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Erythropoietin (EPO)
  • 1.2.3 Human Growth Hormone (HGH)
  • 1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
  • 1.2.5 Monoclonal Antibody (mAb)
  • 1.2.6 Insulin
  • 1.2.7 Interferon (IFN)
  • 1.2.8 Others
• 1.3 Market by Application
  • 1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2020 VS 2026
  • 1.3.2 Anti-Cancer
  • 1.3.3 Anti-Inflammatory/Autoimmune
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2015-2026)
• 2.2 Global Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Regions
  • 2.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Share by Regions (2015-2020)
  • 2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Market Size
  • 3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2015-2020)
  • 3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2015-2020)
• 3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
• 3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
  • 3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2019
• 3.5 Key Players Monoclonal antibodies (mAbs) Biosimilars Area Served
• 3.6 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
• 3.7 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type (2015-2026)

• 4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2015-2020)
• 4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2021-2026)

5 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application (2015-2026)

• 5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2015-2020)
• 5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
• 6.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
• 6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
• 6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
• 7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
• 7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
• 7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
• 8.2 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
• 8.3 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
• 8.4 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
• 9.2 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
• 9.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
• 9.4 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
• 10.2 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
• 10.3 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
• 10.4 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Biocon
  • 11.1.1 Biocon Company Details
  • 11.1.2 Biocon Business Overview
  • 11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020))
  • 11.1.5 Biocon Recent Development
• 11.2 Celltrion
  • 11.2.1 Celltrion Company Details
  • 11.2.2 Celltrion Business Overview
  • 11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.2.5 Celltrion Recent Development
• 11.3 Dr. Reddy's Laboratories
  • 11.3.1 Dr. Reddy's Laboratories Company Details
  • 11.3.2 Dr. Reddy's Laboratories Business Overview
  • 11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.3.5 Dr. Reddy's Laboratories Recent Development
• 11.4 Hospira
  • 11.4.1 Hospira Company Details
  • 11.4.2 Hospira Business Overview
  • 11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.4.5 Hospira Recent Development
• 11.5 3SBio
  • 11.5.1 3SBio Company Details
  • 11.5.2 3SBio Business Overview
  • 11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.5.5 3SBio Recent Development
• 11.6 Accord Healthcare
  • 11.6.1 Accord Healthcare Company Details
  • 11.6.2 Accord Healthcare Business Overview
  • 11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.6.5 Accord Healthcare Recent Development
• 11.7 AET Biotech
  • 11.7.1 AET Biotech Company Details
  • 11.7.2 AET Biotech Business Overview
  • 11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.7.5 AET Biotech Recent Development
• 11.8 Allergan
  • 11.8.1 Allergan Company Details
  • 11.8.2 Allergan Business Overview
  • 11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.8.5 Allergan Recent Development
• 11.9 Amega Biotech
  • 11.9.1 Amega Biotech Company Details
  • 11.9.2 Amega Biotech Business Overview
  • 11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.9.5 Amega Biotech Recent Development
• 11.10 Others
  • 11.10.1 Others Company Details
  • 11.10.2 Others Business Overview
  • 11.10.3 Others Monoclonal antibodies (mAbs) Biosimilars Introduction
  • 11.10.4 Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
  • 11.10.5 Others Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer